The development of therapeutics for personalized medicine leverages many of the advantages of the legislation conferred upon orphan products. New products must be positioned intelligently to take advantage of this legislation. Join David Shoemaker, Ph.D. as he discusses the benefits of orphan product designation in the US, EU, and strategies for obtaining these designations for novel products.
Senior Vice President R&D
- What Non-statisticians Need to Know about Statistics in Clinical Trials
- Using FDA’s Draft Guidance on Risk-Based Monitoring to Improve Clinical Data Quality
- PDUFA V: What you need to know about the upcoming Prescription Drug User Fee Act
- Stop the pain: Tips for increasing patient retention and decreasing missing data in analgesia clinical trials